A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer
Public ClinicalTrials.gov record NCT01565083. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer
Study identification
- NCT ID
- NCT01565083
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 213 participants
Conditions and interventions
Conditions
Interventions
- Pertuzumab Drug
- Trastuzumab Drug
- Vinorelbine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2012
- Primary completion
- Sep 30, 2015
- Completion
- Sep 30, 2015
- Last update posted
- Nov 21, 2016
2012 – 2015
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tucson | Arizona | 85724 | — |
| Not listed | Stanford | California | 94305-5151 | — |
| Not listed | Denver | Colorado | 80220 | — |
| Not listed | Hollywood | Florida | 33021 | — |
| Not listed | Miami | Florida | 33136 | — |
| Not listed | Plantation | Florida | 33324 | — |
| Not listed | Marietta | Georgia | 30060 | — |
| Not listed | Boston | Massachusetts | 02215 | — |
| Not listed | Morristown | New Jersey | 07960 | — |
| Not listed | Durham | North Carolina | 27710 | — |
| Not listed | Columbus | Ohio | 43210 | — |
| Not listed | Houston | Texas | 77090 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Ogden | Utah | 84403 | — |
| Not listed | Fredericksburg | Virginia | 22408 | — |
| Not listed | Seattle | Washington | 98101 | — |
| Not listed | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01565083, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 21, 2016 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01565083 live on ClinicalTrials.gov.